Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 579-583

  Karaman, Serap ^a   Vural, Sema ^a   Yildirmak, Yildiz ^a   Emecen, Merve ^a   Erdem, Ela ^a   Kebudi, Rejin ^b  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cefoperazone sulbactam; Childhood cancer; Febrile neutropenia; Monotherapy; Pediatric cancer; Piperacillin tazobactam

Indexed keywords

AMIKACIN; ANTINEOPLASTIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TEICOPLANIN;

ABSENCE OF SIDE EFFECTS; ACUTE LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEFOPERAZONE; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; SULBACTAM; TIME FACTORS;

EID: 84856829050     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23245     Document Type: Article

References (38)

1. Walsh TJ, Roilides E, Groll AH, et al. Infectious complications in the pediatric cancer patient. In: Pizzo PA, Poplac DG, editors. Principles and practices of pediatric oncology, 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp. 1236-1329.
2. Hughes WT, Armstrong D, Bodey GP, et al. guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
3. Klastersky J. Therapy of infections in cancer patients. In: Klastersky J, Schimpff SC, Senn HJ, editors. Handbook of supportive care in cancer. NewYork: Marcel Dekker, Inc. 1995. pp. 1-44.
4. Hughes WT, Armstrong D, Bodey GP, et al. guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-573.
5. Fanci R, Bartolozzi B, Longo G, et al. A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of fever in patients with acute leukemia. J Chemother 2008; 20: 492-496.
6. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: A review. J Chemother 1996; 8: 375-381.
7. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents 2003; 21: 393-402.
8. Del Favero A, Menichetti F, Martino P, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-1301.
9. Kebudi R, Görgün O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001; 36: 434-441.
10. Payne DJ, Cramp R, Winstanley DJ, et al. Comparative activities of clavulanic acid, sulbactam and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother 1994; 38: 767-772.
11. Body GP, Miller P, Ho DH. Invitro assesment of sulbactam plus cefaperazone in the treatment of bacteria isolated from cancer patients. Diag Microb Infect Dis 1989; 12: 209-214.
12. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397-401.
13. Gur D, Hascelik G, Aydin N, et al. Antimicrobial resistance in gram-negative hospital isolates: Results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21: 383-389.
14. Prabhash K, Medhekar A, Biswas S, et al. Comparison of in vitro activities of ceftazidime, piperacillin-tazobactam, and cefoperazone-sulbactam, and the implication on empirical therapy in patients with cancer. Indian J Cancer 2009; 46: 318-322.
15. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
16. Paul M, Benuri Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 2003; 326: 1111.
17. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176-189.
18. Corapcioglu F, Sarper N, Zengin E. Monotheray with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comprasion. Pediatr Hematol Oncol 2006; 23: 177-186.
19. Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 2008; 51: 774-777.
20. Kobayashi R, Sato T, Nakajima M, et al. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol 2009; 314: 270-273.
21. Simon A, Lehrnbecher T, Bode U, et al. Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: A retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2007; 26: 801-806.
22. Kebudi R, Ayan I, Gorgun O, et al. Piperacillin-tazobactam versus cefepime monotherapy for pediatric febrile neutropenia. Proceedings of American Society of Clinical Oncology. J Clin Oncol 2005; 23: 812s (abstract 8550).
23. Haddad MA. Comparison of cefaperazone-sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Curr Ther Res 1995; 56: 1094-1099.
24. de Souza Viana, Serufo L, da Costa JC, et al. et al. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2008; 16: 841-846.
25. Tromp YH, Daenen SM, Sluiter WJ, et al. The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia. Eur J Cancer 2009; 45: 596-600.
26. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Clin Oncol 2000; 16: 3038-3051.
27. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 2000; 2: 107-111 (review).
28. Blot F, Guiguet M, Nitenberg G, et al. Prognostic factors for neutropenic patients in an intensive care unit: Respective roles of underlying malignancies and acute organ failures. Eur J Cancer 1997; 33: 1031-1037.
29. Vural S, Erdem E, Gulec SG, et al. Imi{dotless}penem ci{dotless}lastati{dotless}n Versus pi{dotless}peraci{dotless}lli{dotless}n tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2009; 52: 262-267.
30. Vural S, Meral G, Urganci N, et al. Seftazidime in febrile neutropenia. Türk Onkoloji Dergisi 2000; 15: 103-106.
31. Vural S, Urganci N, Öztürk M, et al. Febril Nötropenik Çocuk Hastalarda İmipenem-Silastatin. Klimik Dergisi 2001; 14: 10-13.
32. Paul M, Gafler-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: Experience from a single center. 1988-2004. Isr Med Assoc 2007; 9: 424-429.
33. Kebudi R, Vural S, Anak S. Pediatric febrile neutropenia activities in Turkey. Pediatr Blood Cancer 2005; 45: 513 (abstract PG'.023).
34. Pfaller MA, Herwaldt LA. Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci. Clin Microbiol Rev 1988; 1: 281-299.
35. Herwaldt LA, Hollis RJ, Boyken LD, et al. Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. Infect Control Hosp Epidemiol 1992; 13: 86-92.
36. Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: A single-center, randomized, controlled trial in Argentina. Cancer 2003; 97: 1775-1780.
37. Gupta A, Swaroop C, Agarwala S, et al. Randomized control trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009; 31: 635-641.
38. Vidal L, Paul M, Ben dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004; 54: 29-37.